Cesca Therapeutics Inc. (NASDAQ:KOOL) an autologous cell-based regenerative medicine company, announced longer-term follow up from its feasibility study of SurgWerks(R)-CLI, its candidate therapeutic device kit for treating Rutherford category 5 and Fontaine IV (end-stage) critical limb ischemia (“CLI”). Cesca Therapeutics Inc. (NASDAQ:KOOL) stock opened today at $1.93 and is currently trading at $1.89. The stock showed a positive weekly performance of 8.77%.
Halozyme Therapeutics Inc. (NASDAQ:HALO) announced that it is resuming its ongoing Phase II trial of PEGPH20 in patients with pancreatic cancer following the U.S. Food and Drug Administration’s (FDA) removal of its clinical hold on patient enrollment and dosing in the study. Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock opened at $9.18, in current trading session and currently is at $9.33, by gaining 1.74%. The 52 week range of $5.88 – $18.18. Company’s market capitalization is 1.16 billion.
Vermillion Inc. (NASDAQ:VRML) on 15 may, Thursday posted a loss of $4.2 million in the first quarter, or 11 cents per share, on revenue of $305,000, compared to a loss of $2.6 million, or 17 cents per share, on revenue of $328,000 in the year-earlier period. Vermillion, Inc. (NASDAQ:VRML) stock is currently trading at $2.78. The EPS of the stock is -0.45. Company’s market capitalization is 99.61 million.
The Shareholders Foundation announces that an investigation on behalf of investors of POZEN Inc. (NASDAQ:POZN) shares was initiated over potential securities laws violations by POZEN and certain of its directors and officers in connection certain financial statements was announced. POZEN Inc. (NASDAQ:POZN) stock opened the session at $9.41, and now is at $9.42. The 52 week range of the POZEN Inc. (NASDAQ:POZN) stock remained $4.73 – $9.90 and the day range was $9.20 – $9.44.
Mast Therapeutics Inc. (NYSEMKT:MSTX) on May 5 reported financial results for the quarter ended March 31, 2014. The Company’s net loss for the first quarter of 2014 was $6.4 million, or $0.06 per share (basic and diluted), compared to a net loss of $5.6 million, or $0.12 per share (basic and diluted), for the same period in 2013. Research and development expenses for the first quarter of 2014 were $4.3 million, an increase of $0.9 million, or 24%, compared to $3.4 million for the same period in 2013. Mast Therapeutics Inc. (NYSEMKT:MSTX) stock opened today at $0.64 and is currently trading at $0.630. The stock showed a negative weekly performance of -3.08%.